长药控股(300391) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥128,646,477.00, a decrease of 51.03% year-on-year[7]. - Net profit attributable to shareholders was -¥18,459,300.55, representing a decline of 145.54% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥19,891,442.28, down 152.15% year-on-year[7]. - Basic earnings per share were -¥0.0527, a decrease of 130.29% compared to the same period last year[7]. - The weighted average return on net assets was -1.26%, a decline of 144.68% year-on-year[7]. - The company's total net profit for the year-to-date period was CNY 25,545,500.03, compared to CNY 105,710,066.85 in the previous year[44]. - The total comprehensive income for the year-to-date period was CNY 8,939,214.62, compared to CNY 9,870,381.65 in the previous year[44]. - The net profit for the current period is -¥2,486,393.05, a significant drop from ¥17,965,526.02 in the previous period[48]. - Basic and diluted earnings per share are both ¥0.0779, down from ¥0.4662 in the previous period[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,127,293,035.67, an increase of 2.07% compared to the previous year[7]. - Total current assets increased to ¥1,106,082,094.33 from ¥1,041,105,324.25[27]. - Total liabilities increased to ¥672,842,765.18 from ¥652,600,457.23[28]. - The company's total liabilities amounted to CNY 507,595,149.20, compared to CNY 473,582,643.58 in the previous year, reflecting an increase of 7.0%[33]. - The equity attributable to shareholders of the parent company was CNY 1,261,988,156.46, down from CNY 1,276,152,419.91, a decrease of 1.1%[34]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥63,578,830.84, down 39.03% compared to the previous year[7]. - Net cash flow from operating activities decreased to $21,276,464.09 from $36,468,883.84, a decline of 41.6%[56]. - Cash received from sales and services was $162,568,973.76, slightly lower than $164,940,614.03 in the previous period[56]. - Cash paid for purchasing goods and services was $72,057,080.36, up from $64,154,160.06, an increase of 12.5%[56]. - Cash paid to employees increased to $31,133,637.79 from $26,670,853.84, reflecting an increase of 16.4%[56]. - Cash paid for taxes rose to $10,632,154.98 from $7,455,405.79, an increase of 42.9%[56]. Expenses - Management expenses increased by 30.40% to ¥68,590,855.45 compared to ¥52,599,320.31 in the previous period[18]. - Financial expenses rose by 44.52% to ¥14,429,004.29 due to increased financing costs[18]. - Other income decreased by 41.62% to ¥11,692,787.70, primarily due to a reduction in government subsidies received[18]. - Income tax expenses dropped by 62.09% to ¥4,920,309.74, attributed to a decline in profits[18]. - The company reported a significant increase in financial expenses, totaling CNY 3,622,150.30, compared to CNY 1,900,445.86 in the previous year[39]. Shareholder Information - The company had a total of 14,887 common shareholders at the end of the reporting period[11]. - The largest shareholder, Shouguang Kangyue Investment Co., Ltd., held 45.39% of the shares, amounting to 159,001,272 shares[11]. Research and Development - Research and development expenses for Q3 2019 were CNY 10,662,755.24, compared to CNY 9,564,600.40 in Q3 2018, indicating an increase of 11.5%[36]. - Research and development expenses for the third quarter were CNY 4,834,120.47, slightly down from CNY 5,677,759.66 in the previous year[39]. - Research and development expenses remained stable at ¥16,237,652.11, slightly up from ¥16,194,448.24[47].